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Abstract
Introduction: The significance of lymph node metastases and the optimal extent of lymphadenectomy remain matters of controversy in 
papillary thyroid cancer. 
This study was designed to assess the feasibility and reliability of OSNA and real-time PCR for CK19 and TG mRNA in papillary thyroid 
cancer lymph nodes evaluation compared to standard histopathology. 
Material and methods: Each of 92 randomised lymph nodes from 32 papillary thyroid cancer patients were divided into representative 
parts and assessed using the three studied methods. 
Results: Eighteen (19.6%) lymph nodes from ten (31.3%) patients were positive according to histopathology. When the cut-off value 
distinguishing metastatic from non-metastatic lymph nodes in the OSNA assay was set at 250 copies per microlitre, the results were 
positive in 16 (17.4%) lymph nodes from 11 (34.4%) patients. Twenty three (25%) lymph nodes were tested positive in real-time PCR for 
TG mRNA. Real-time PCR for CK19 mRNA was positive in 18 (19.6%) lymph nodes from 13 (40.6%) patients. No statistically significant 
differences were noted between the diagnostic accuracy of either molecular method compared to the histopathological examination 
(p = 0.81). Overall, 20 positive molecular biology results were noted in patients with negative histopathology results. Conversely, 
in 18 lymph nodes, despite a metastasis finding in histopathology, at least one molecular test yielded a negative result. 
Conclusions: It was revealed that OSNA is a reliable technique for the evaluation of lymph node metastases in papillary thyroid cancer. 
This method was shown to have equivalent accuracy to histopathology and real-time PCR. (Endokrynol Pol 2014; 65 (6): 422–430)
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Streszczenie
Wstęp: Znaczenie przerzutów do węzłów chłonnych oraz optymalny zakres limfadenektomii w raku brodawkowatym tarczycy pozostaje 
przedmiotem kontrowersji. 
Celem pracy była ocena wykonalności oraz zgodności wyników jednostopniowej amplifikacji kwasu nukleinowego oraz PCR w czasie 
rzeczywistym dla CK19 i TG mRNA w badaniu węzłów chłonnych w raku brodawkowatym tarczycy w porównaniu z rutynowym ba-
daniem histopatologicznym. 
Materiał i metody: Każdy z 92 węzłów chłonnych pochodzących od 32 pacjentów z rakiem brodawkowatym tarczycy został podzielony 
na reprezentatywne części i zbadany trzema metodami. 
Wyniki: Osiemnaście (19,6%) węzłów chłonnych od 10 (31,3%) pacjentów miało dodatni wynik badania histopatologicznego. Przyjmując 
wartość odcięcia 250 kopii w mikrolitrze, różnicującej węzły chłonne zmienione przerzutowo od niezmienionych, w badaniu jednoeta-
powej amplifikacji kwasu nukleinowego, stwierdzono dodatni wynik badania w 16 (17,4%) węzłach chłonnych od 11 (34,4%) pacjentów. 
Uzyskano dodatni wynik badania PCR w czasie rzeczywistym dla TG mRNA w 23(25%) węzłach chłonnych, natomiast dla CK19 mRNA 
w 18 (19,6%) od 13 (40,6%) pacjentów. Nie stwierdzono istotnej statystycznie różnicy pomiędzy zgodnością wyników obu metod mo-
lekularnych z wynikiem badania histopatologicznego (p = 0,81). Ogólnie stwierdzono 20 dodatnich wyników badania molekularnego 
z węzłów chłonnych, przy ujemnym wyniku badania histopatologicznego. Natomiast w 18 węzłach, pomimo znalezienia przerzutów 
w badaniu histopatologicznym, uzyskano ujemny wynik w przynajmniej jednym badaniu molekularnym. 
Wnioski: Badanie jednostopniową amplifikacją kwasu nukleinowego jest właściwą metodą oceny obecności przerzutów w węzłach 
chłonnych w raku brodawkowatym tarczycy. Technika ta ma zbliżona wiarygodność do badania histopatologicznego i badania PCR 
w czasie rzeczywistym. (Endokrynol Pol 2014; 65 (6): 422–430)
Słowa kluczowe: OSNA; histopatologia; badanie PCR w czasie rzeczywistym; węzły chłonne; rak brodawkowaty tarczycy
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compartment of the neck in patients with unaffected 
lymph nodes in the central compartment. The lateral skip 
metastasis rate in patients with thyroid cancer has been 
reported to be as high as 20%, and the rate of contralateral 
lymph node involvement as high as 18% [21, 22]. Despite 
these advantages, it is probably too early to consider the 
SLNB method as a standard of examination in the treat-
ment of the PTC patients. If this technique becomes more 
common, it could be possible to apply the method in the 
intraoperative examination of lymph nodes. Applying the 
abovementioned methods will allow reoperation to be 
avoided. Additionally, it is impossible to intraoperatively 
examine the entire LN using frozen sections, which may 
lead to false-negative results. Indeed, the sensitivity of the 
intraoperative frozen section for finding nodal metastases 
within SNs during surgery has been reported to be 47% in 
melanoma patients and 74% in breast cancer patients [23]. 
The sensitivity of touch imprint cytology is comparable to 
that of frozen section examination [24, 25]. 
In order to find other methods of thyroid cancer 
lymph node evaluation, we tried to establish a new 
intra-operative molecular diagnostic tool. Currently 
there are two molecular techniques used for intraopera-
tive assessment. Real-time PCR has been employed to 
estimate lymph nodes in PTC yet it is still in the research 
stage and is not yet used in clinical practice [26, 27]. To 
the best of our knowledge, PTC lymph nodes have not 
yet been evaluated by one-step nucleic acid amplifica-
tion (OSNA). It has been demonstrated that CK19 can 
be used as a marker of PTC in immunohistochemical 
and molecular examinations [8, 28–31]. If the sentinel 
lymph node biopsy is introduced to thyroid surgery, 
OSNA could be a reasonable alternative to ‘classical’ 
intraoperative examinations. Probably OSNA could 
replace frozen section examination of lymph nodes 
in differentiating between benign and malignant 
follicular-type of the thyroid gland. 
This study was designed to assess the feasibility and 
reliability of OSNA and real-time PCR for CK19 and TG 
mRNA in PTC lymph nodes evaluation compared to 
standard histopathology. 
Material and methods
The study was performed in concordance with the 
outlines of the Ethical Commission of the Medical Uni-
versity of Łódź and in compliance with the Declaration 
of Helsinki. Real-time PCR and OSNA did not affect the 
operation procedure. 
Characteristics of patients
A prospectively recruited cohort of 32 consecutive patients 
with thyroid cancer underwent total thyroidectomy with 
appropriate lymphadenectomy at the Department of Gen-
Introduction
Patients with papillary thyroid cancer (PTC) have 
a high incidence of lymph node metastases. This varies 
from 11% to 90% of patients at the time of surgery or 
histological examination [1–3]. The proper treatment and 
significance of cervical lymph node metastases in PTC is 
controversial. It has been shown in some publications 
that, in subsets of patients, especially younger than 45, 
lymph node metastases do not decrease the survival rate 
[4–6]. Other publications, on the contrary, suggest that 
lymph node involvement is a significant prognostic fac-
tor that increases the risk of locoregional relapse [7] and 
decreases the survival rate [8, 9]. The optimal extent of 
lymph node dissection also remains a matter of debate 
in PTC. It ranges from selective lymphadenectomy to 
a formal comprehensive neck dissection (prophylactic 
lymphadenectomy). Prophylactic lymphadenectomy has 
not yet been accepted by all as a standard management 
of occult metastases, due to the inherent risks of hypocal-
caemia and recurrent laryngeal nerve injury [10]. On the 
contrary, according to others, selective lymphadenectomy 
is not sufficient and is associated with a greater risk of 
local recurrence [7, 9, 11]. Recurrence can appear also in 
patients when the routine histopathology from removed 
lymph nodes has been negative [12]. The significance of 
lymph node metastases and the extent of lymph node 
dissection is a matter of controversy, probably because 
of a lack of suitable diagnostic tools. Today, the clinical 
staging according to the UICC classification depends on 
routine histopathological examination, which eventually 
is allied with immunohistochemistry. In other cancers, the 
situation is different [13, 14]. We hope that introducing mo-
lecular methods will improve the assessment of PTC. The 
reverse-transcription polymerase chain reaction (RT-PCR) 
is used to analyse tumour-specific mRNA. As a molecular 
biology-based technique, it has been shown to be useful 
in detecting lymph node metastases. This method shows 
a higher sensitivity for revealing minor tumour deposits 
in lymph nodes compared to conventional histopathology 
[15–17]. However, this method is not yet used in routine 
clinical practice, due to its complexity and time-consuming 
nature. Moreover, it cannot be used as an intraoperative 
examination. The sentinel lymph node biopsy (SLNB) has 
been introduced to limit the extent of lymphadenectomy 
in PTC patients [18–20]. There are several advantages of 
the SLNB in clinical practice. It may identify patients who 
can benefit from lymph node dissection in the central and 
lateral compartment of the neck. SLNB finds lymph nodes 
which are at a high risk of metastases. These lymph nodes 
should be evaluated carefully. An intensive examination 
of the rest of the cervical lymph nodes may be impracti-
cal and expensive. Another important benefit of SLNB 
is that it can detect involved lymph nodes in the lateral 
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eral and Oncological Surgery of the Medical University 
of Łódź, Poland from 1 April, 2011 to 1 March, 2013. They 
were suspected or diagnosed with thyroid carcinoma 
based on FNAB. The patients were primarily operated. 
Patients admitted to the Department for completion 
thyroidectomy or removing relapse were excluded from 
the study. The type of operation was consistent with the 
guidelines of the Polish Society of Surgeons and the Pol-
ish Society of Oncological Surgery [32]. The study group 
consisted of seven (21.9%) men and 25 (78.1%) women 
with a mean age of 46.7. The patients were diagnosed 
with the classical subtype of PTC N = 29 (90.6%), follicular 
subtype of PTC N = 2 (6.3%), and oxyphilic subtype of 
PTC N = 1 (3.1%) (Table I). None of the patients had any 
significant comorbidities. Two patients were not included 
for the study because informed consent was not obtained. 
Lymph nodes samples division 
The number of evaluated nodes from each individual 
ranged from one to six. The diameter of lymph nodes 
ranged from 8 mm to 13 mm. All lymph nodes were 
separated from fat tissue before division. Each of the 
92 randomised lymph nodes was divided into repre-
sentative parts and assessed using the three studied 
methods. Firstly, they were divided into four blocks 
by a sterile, single use, special cutting device in the 
same way as in the clinical protocol study performed 
by Tsujimoto et al. [33]. In our procedure, blocks a and 
c were used for OSNA. Blocks b and d were cut along 
the longitudinal axis into representative sections for 
histopathology and real-time PCR. We did not have 
enough material to perform immunohistochemistry.
Histopathology procedure 
The final histological examination consisted of a de-
tailed analysis of the lymph node tissue sections embed-
ded in paraffin blocks. All specimens were examined by 
an experienced specialist of clinical pathology, using 
a conventional optical microscope. The pathologist 
who performed the histopathological evaluation was 
blinded to real-time PCR and OSNA results.
Real-time PCR procedure 
The reverse transcription reaction was performed using 
the commercially available set of High Capacity cDNA 
Archive Kit (Applied Biosystems, USA) in the manufac-
turer’s facilities. RNA extraction was performed using 
TRI Reagent (Sigma-Aldrich, St. Louis, MO, USA). For 
the reverse transcription reaction, random hexamer 
primers were used, according to the manufacturer’s 
instructions —10 min 25°C, 2 h 37°C, and 4°C thereafter. 
Ct values of TG and CK-19 indeed showed a large 
variability but the dCt values before and after reverse 
transcription did not deviate by more than ± 15% 
without any biased deviation in samples positive and 
negative for the presence of tumour cells. This led us 
to believe us that RT did not introduce any significant 
bias and we used cDNA in further analyses.
For OSNA this step could well be omitted, accelerat-
ing the time-to-result. However, for the purpose of this 
study we used reverse transcription to obtain stable 
cDNA material for further tests of method comparisons 
and long-term storage. 
The cDNA/RNA content in samples after isolation 
was measured using the spectroscopic method on the 
Table I. Histological subtype and number of examined nodes
Tabela I. Podtyp histologiczny i liczba zbadanych węzłów 
chłonnych
Patient Histopathology N nodes
1 Classical subtype of PTC 3
2 Classical subtype of PTC 1
3 Classical subtype of PTC 5
4 Classical subtype of PTC 3
5 Classical subtype of PTC 2
6 Classical subtype of PTC 5
7 Classical subtype of PTC 3
8 Classical subtype of PTC 2
9 Classical subtype of PTC 2
10 Classical subtype of PTC 2
11 Classical subtype of PTC 3
12 Classical subtype of PTC 1
13 Classical subtype of PTC 2
14 Classical subtype of PTC 3
15 Classical subtype of PTC 1
16 Classical subtype of PTC 1
17 Classical subtype of PTC 2
18 Classical subtype of PTC 3
19 Classical subtype of PTC 4
20 Classical subtype of PTC 6
21 Classical subtype of PTC 3
22 Oxypholic subtype of PTC 4
23 Classical subtype of PTC 1
24 Classical subtype of PTC 6
25 Classical subtype of PTC 3
26 Classical subtype of PTC 5
27 Classical subtype of PTC 4
28 Classical subtype of PTC 3
29 Follicular subtype of PTC 1
30 Classical subtype of PTC 3
31 Classical subtype of PTC 2
32 Follicular subtype of PTC 3
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NanoDrop device (NanoDrop, Wilmington, DE, USA). 
260/280 ratios > 1.9 were considered acceptable. 
The resulting cDNA was diluted to a final concentra-
tion of 5 ng/μl and used as a matrix in further experiments. 
Real-time PCR was performed using Taqman probes spe-
cific for TGc and CK-19 (assay numbers Hs00794359_m1 
and Hs00761767_s1 (Applied Biosystems, Foster City, CA, 
USA), referenced with GAPDH expression level. Mean Ct 
of GAPDH was 25.68 ± 1.43 and was stable throughout 
the dataset. Comparative analyses of each of these genes 
in individual patients were performed using specialised 
computer programs SDS2.3 and RQ 2.1 (Applied Biosys-
tems, Foster City, CA, USA). All amplification reactions 
were performed in duplicates. The mRNA expression 
levels of TG and CK-19 were calculated using the 2–dCt [34]. 
All molecular studies were performed by an experienced 
molecular biologist/geneticist independently from the 
histopathology procedure and the results of molecular 
studies did not affect therapeutic decisions. 
OSNA procedure
The OSNA protocol for each lymph node consisted 
of homogenisation of tissue in a mRNA-stabilising 
solution and subsequent amplification. It was made 
automatically by reverse transcription loop-mediated 
isothermal amplification (RT-LAMP) of CK19 mRNA in 
the RD-100i detection engine (Sysmex) without prior 
mRNA isolation and purification. RD-100i includes 
a ready-to-use reagent kit (Lynoamp, Sysmex) consist-
ing of the enzyme, primers, nucleotides, buffer neces-
sary for CK19 mRNA amplification and components 
for assay validation (calibrators, positive and negative 
controls). The technique uses six primers, which in-
crease the specificity and speed of the reaction. The 
expression level of CK19 mRNA is detected by real-time 
monitoring of turbidity changes caused by an increase 
in the magnesium pyrophosphate concentration, 
a by-product of the amplification reaction. Results are 
automatically characterised by the CK19 mRNA copy 
number/LL of the original tissue homogenate in accord-
ance with cut-off levels defined by Tsujimoto et al. [33]. 
The study was focused on comparing lymph nodes 
with or without metastases detectable in histopathol-
ogy. We did not use lymph nodes from healthy indi-
viduals as additional controls due to ethical concerns, as 
well as due to the sufficient number of histopathology 
negative lymph nodes for comparison purposes.
Statistical analysis
Continuous variables were compared using Mann-
Whitney’s U test. Categorical variables were compared 
using Yates’ corrected Chi2 test or McNemar’s Chi2 test for 
dependent cases. Receiver operating characteristic (ROC) 
curves were constructed to establish optimal cut-off scores 
for continuous variables. Statistical 10.0 software was used 
for analysis (Statsoft, Tulsa, OK, USA). 95% Confidence 
Intervals were computed where possible. A p value lower 
than 0.05 was considered as statistically significant. 
Results
Histopathology results 
Eighteen (19.6%) lymph nodes from ten (31.3%) patients 
were positive. According to histopathology, no metas-
tases were found in 63 (68.5%) regional lymph nodes 
coming from 22 (68.7%) patients.
OSNA results 
When the cut-off value distinguishing metastatic from 
non-metastatic lymph nodes in the OSNA assay was set 
at 250 copies per microlitre, the results were positive in 
16 (17.4%) lymph nodes from 11 (34.4%) patients. The re-
sults for lymph nodes in 21 (65.6%) patients were negative. 
Real-time PCR
Expression of CK-19 and TG differed significantly (both 
p values < 0.0001) depending on the result of histo-
pathological examination (Figures 1 and 2 respectively).
Cut-off values for real-time PCR were selected using 
the ROC curve analysis and they provided clinically-ef-
ficient discrimination of lymph nodes with and without 
metastatic cancer cells (Table II). Results of the OSNA 
tests were close to real-time PCR measurements of TG 
and CK-19, but provided respectively one and three 
additional erroneous measurements (Table II). 
Diagnostic efficacy of OSNA measurements and real-
time-PCR for TG and CK-19. 95% Confidence Interval 
(95% CI). Areas under the ROC curve equalled 0.82 (95% 
CI 0.72–0.89) for TG and 0.81 (95% CI 0.71–0.88) for CK19. 
No statistically significant differences were noted 
between the diagnostic accuracy of either method com-
pared to the histopathological examination (p = 0.81). 
Discordance cases analysis 
Clinical data
Discordant cases between histopathology and OSNA 
results
The results were discordant in seven (7.6%) lymph 
nodes. The OSNA assay was positive in three lymph 
nodes, while it was negative in histopathology. OSNA 
was not able to detect metastases in four histopathology 
positive lymph nodes. 
Real-time PCR for TG mRNA results
23 (25%) lymph nodes were tested positive in this 
examination. They came from 12 (37.5%) patients. The 
lymph nodes in 20 (62.5%) patients were negative. 
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Discordant cases between histopathology and real-
time PCR for TG mRNA results
The results were discordant in 11 (12%) lymph nodes 
from five (15.6%) patients. Eight (8.7%) lymph nodes 
were positive in real-time PCR although there were no 
metastases in these nodes according to histopathology. 
On the other hand, molecular examination was not 
able to detect metastases in three (3.3%) histopathology 
positive lymph nodes. 
Real-time PCR for CK19 mRNA results
This molecular technique was positive in 18 (19.6%) 
lymph nodes from 13 (40.6%) patients. The other 
19 (59.4%) patients had negative results in all lymph nodes. 
Discordant cases between histopathology  
and real-time PCR for CK19 mRNA results
Discordant results between these examinations 
were observed in ten (9.2%) lymph nodes. Five of 
them were positive only in the molecular examina-
tion. On the contrary, metastases were observed 
only in histopathological examination in five lymph 
nodes. No significant bias for false positive or false 
negative results was detected when comparing real-
time PCR for TG vs. OSNA (McNemar ’s Chi-square 
test p = 0.64), OSNA vs. real-time PCR for CK-19 
(p = 1.00) and real-time PCR for TG vs. real-time PCR 
for CK-19 (p = 0.45). 
Curiously false positive and false negative lymph 
nodes overlapped poorly between the three methods 
(Figs. 3–5) with ten discordant cases in all three combi-
nations of molecular methods (OSNA vs. real-time PCR 
for TG, OSNA vs. real-time PCR for CK-19 and real-time 
PCR for CK-19 vs. real-time PCR for TG.
None of the lymph nodes was detected to be falsely 
negative by all three methods; two were negative for 
real-time PCR for TG and CK-19; and another two were 
negative for CK-19 real-time PCR and OSNA. Clustering 
of erroneous results was observed in OSNA and TG 
real-time PCR measurements (Figs. 6, 7). 
Figure 1. Thyroglobulin (TG) mRNA expression levels in 
lymph nodes with and without metastatic cancer cells detected in 
histopathological examination
Rycina 1. Poziomy ekspresji mRNA dla tyreoglobuliny (TG) 
w węzłach chłonnych z obecnością lub bez komórek nowotworowych 
w badaniu histopatologicznym 
Figure 2. Cytokeratin 19 (CK-19) mRNA expression levels in 
lymph nodes with and without metastatic cancer cells detected in 
histopathological examination
Rycina 2. Poziomy ekspresji mRNA dla cytokeratyny (CK-19) 
w węzłach chłonnych z obecnością lub bez komórek nowotworowych 
w badaniu histopatologicznym 
Table II. Diagnostic efficacy of OSNA measurements and Real-time-PCR for TG and CK-19. 95%CI — 95% Confidence Interval. 
Areas under the ROC curve equalled 0.82 (95% CI 0.72-0.89) for TG and 0.81 (95% CI 0.71-0.88) for CK19
Tabela II. Skuteczność diagnostyczna badań OSNA i PCR w czasie rzeczywistym dla TG i CK-19. 95-procentowy przedział 
ufności. Pola pod krzywą ROC wynosiły 0,82 (95% CI 0,72–0,89) dla TG i 0,81(95% CI 0,71–0,88) dla CK19
Cutt-off Sensitivity Specificity PPV NPV
TG < 3.25 75% 89% 65% 93%
CK-19 < 6.34 70% 93% 92% 74%
OSNA N.A. 65% 90% 65% 90%
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Overall, 20 positive molecular biology results were 
noted in patients with negative histopathology results, 
and were considered false positives. Those 20 results 
were observed in 13 individual samples, of which in 
five cases two methods yielded a concordant positive 
results despite the apparent absence of tumour cells 
in the histopathological examination. In one case, all 
three molecular methods showed evidence of tumour 
cells. Conversely, in 18 lymph nodes despite a positive 
histopathological result, at least one molecular test 
yielded a negative result. Of those 18 cases, four sam-
ples were termed negative by two methods and as such 
Figure 3. Overlap of lymph nodes marked as positive in one-
step nucleic acid amplification (OSNA), Real-time PCR for 
CK19 and histopathology. All three molecular methods and the 
histopathological examination yielded concordant, negative results 
in 60 cases
Rycina 3. Zgodność dodatnich wyników z węzłów chłonnych 
w badaniu jednoetapowej amplifikacji kwasu nukleinowego 
(OSNA), PCR w czasie rzeczywistym dla CK19, i histopatologii. 
Metody molekularne i histopatologia dały zgodne, ujemne wyniki 
w 60 przypadkach
Figure 4. Overlap of lymph nodes marked as positive in 
one-step nucleic acid amplification (OSNA), real-time PCR 
for thyroglobulin (TG) and histopathological examination. 
Molecular methods and the histopathological examination yielded 
a concordant, negative results in 58 cases
Rycina 4. Zgodność dodatnich wyników z węzłów chłonnych 
w badaniu jednoetapowej amplifikacji kwasu nukleinowego 
(OSNA), PCR w czasie rzeczywistym dla tyreoglobuliny (TG), 
i histopatologii. Metody molekularne i histopatologia dały zgodne, 
ujemne wyniki w 58 przypadkach
Figure 5. Overlap of lymph nodes marked as positive in Real-
time PCR for thyroglobulin (TG) or cytokeratin 19 (CK-19) 
and histopathological examination. Molecular methods and the 
histopahological examination yielded a concordant, negative 
result in 60 cases
Rycina 5. Zgodność dodatnich wyników z węzłów chłonnych 
w badaniu PCR w czasie rzeczywistym dla tyreoglobuliny 
(TG) i CK-19 (CK-19) i histopatologii. Metody molekularne 
i histopatologia dały zgodne, ujemne wyniki w 60 przypadkach
Figure 6. Overlap of false positive results in one step nucleic acid 
amplification (OSNA) and thyroglobulin (TG) or cytokeratin-19 
real-time-PCR (CK-19)
Rycina 6. Zgodność fałszywie dodatnich wyników w badaniu 
jednoetapowej amplifikacji kwasu nukleinowego (OSNA), 
w badaniu PCR w czasie rzeczywistym dla tyreoglobuliny (TG) 
i cytokeratyny-19 (CK-19)
428
PR
A
C
E 
O
RY
G
IN
A
LN
E
OSNA in papillary thyroid cancer lymph nodes  Krzysztof Kaczka et al.
were categorised as false negative results. Therefore, it 
seems that a greater degree of overlap is observed in 
false positive cases than in false negative ones (Fig. 8), 
suggesting that at least some nodes deemed negative 
in histopathology may in fact contain micrometastases, 
missed due to node sectioning or human error.
Discussion
Histopathological examination, sometimes paired with 
immunonohistochemistry, is a basic technique used to 
assess lymph nodes in thyroid cancer patients, yet it 
does not evaluate the lymph node status precisely. Oc-
cult lymph node metastases can appear in up to 20% of 
thyroid cancer patients [35]. This is possibly caused by 
insufficient lymphadenectomy or/and micrometastases 
that are not found in routine histopathology. This ex-
amination has limited value because only several slides 
from each biological sample are checked. Serious histo-
pathological examination is more sensitive but requires 
much more work to evaluate many slides, so it cannot 
be used as a standard procedure. Perhaps molecular 
methods allow the examination of all the material from 
lymph nodes. Kary Mullis invented the polymerase 
chain reaction (PCR) — a new technique which allows 
millions of DNA copies with required sequences to be 
obtained [36]. Nowadays, there are many types of PCR 
reactions. One of them — the reverse transcriptase-
polymerase chain reaction (RT-PCR) — is often used 
to find metastases in lymph nodes. This method has 
been also tested in thyroid cancer studies [37, 38]. These 
studies suggest that RT-PCR is sensitive enough to 
detect nodal involvement in thyroid cancer. However, 
it is a time-consuming procedure, making it unsuit-
able for intraoperative examination. Real-time PCR 
and OSNA could be used for this purpose. Real-Time 
PCR is a method based on PCR, which is performed 
to amplify and simultaneously quantify specific DNA. 
The median time needed for real-time PCR testing is 
40 minutes, confirming its suitability for intraoperative 
examination. OSNA is quite a new method that uses 
the reverse-transcription loop-mediated isothermal 
amplification (RT-LAMP) technique for gene amplifica-
tion. This technique was invented by Notomi et al. [39]. 
The reaction is performed isothermally by means of six 
primers and is able to detect mRNA of CK19 without 
interference of pseudogenes. The assay can differentiate 
contamination of a few benign epithelial cells by using 
a verified cutoff value. It quantitatively measures the 
levels of CK19 mRNA), which is considered as a marker 
of cancer cells. OSNA was used for the first time in 
breast cancer patients by Tsujimoto et al. [33]. In this 
method, the supernatant of a homogenised lymph 
node solution is directly analysed without the mRNA 
purification process that is usually required in PCR. 
The use of an automated gene amplification machine 
permits a standardised and rapid procedure. A single 
examination takes 30-40 minutes, meaning OSNA can 
be used as an intraoperative examination. OSNA is clini-
cally used for the evaluation of lymph node metastases 
in breast cancer as well as in colorectal cancer, gastric 
cancer and head and neck cancer [40–44]. It uses CK19 
mRNA as a marker. In this study, we decided to com-
pare OSNA and real-time PCR with histopathology as 
a gold standard to detect lymph node metastases of 
PTC. Two markers, TG and CK-19, were used for real-
Figure 7. Overlap of false negative results in one step nucleic acid 
amplification (OSNA) and thyroglobulin (TG) or cytokeratin-19 
real-time-PCR (CK-19)
Rycina 7. Zgodność wyników fałszywie ujemnych w badaniu 
jednoetapowej amplifikacji kwasu nukleinowego (OSNA), 
w badaniu PCR w czasie rzeczywistym dla tyreoglobuliny (TG) 
i cytokeratyny-19 (CK-19)
Figure 8. Overlap of false positive and false negative results
Rycina 8. Zgodność wyników fałszywie dodatnich i ujemnych
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time PCR while CK-19 was used for OSNA. It is a pity 
that there is no commercial TG marker kit for OSNA. In 
our study, 92 lymph nodes were examined. The results 
of OSNA and histopathology were different only in 
seven (7.6%) lymph nodes. Three lymph nodes were 
positive in OSNA while they were negative in histopa-
thology. Curiously, one sample was also positive in both 
real-time PCRs and negative in histopathology. The 
three other samples were negative in real-time PCR. 
These results suggest that alternate parts of the lymph 
nodes, which may or may not enclose cancer cells, were 
taken for the pathology and OSNA, respectively. This 
is so because samples for molecular examination must 
be homogenised. They cannot be used for pathology, 
therefore studies which compare two modalities from 
different slices of the same lymph node must give some 
cases of discrepant results. This is a limitation of such 
studies, yet there is no way of avoiding it. It would 
be interesting to perform OSNA examination on the 
whole lymph node, as is done in breast cancer [45, 46]. 
Unfortunately, since no studies evaluating the accuracy 
of OSNA in thyroid cancer have been carried out, it 
is impossible, from an ethical and legal point of view, 
to perform OSNA instead of histopathology. On the 
contrary, there were four OSNA (–) and histopathol-
ogy (+) lymph nodes. Interestingly, all but one of them 
was positive in both PCR examinations. This sample 
was also positive in one real-time PCR examination. 
These results suggest that OSNA negative results are 
truly negative, and that molecular examination was 
not sensitive enough to detect metastases in these 
lymph nodes. Based on this outcome, we concluded 
that OSNA is a sensitive technique in the detection 
of nodal metastases of the papillary thyroid cancer. In 
eight (8.7%) lymph nodes, metastases were detected 
with RT-PCR for TG mRNA, although the lymph nodes 
were classified histologically as metastasis-free. Perhaps 
this was caused also by a sampling error, or by illegiti-
mate amplification, or pseudogenes. Bojunga et al. and 
Austin et al. described illegitimate amplification in PTC 
[47, 48]. The number of false positive results increases 
with an increased number of PCR cycles. Only one of 
these eight lymph nodes was OSNA (+). This indicates 
that the results of PCR are rather false positive but it 
also impossible to exclude a sampling mistake. On the 
other hand, in three (3.3%) lymph nodes, RT-PCR for 
TG mRNA failed to detect thyroid cancer cells despite 
positive histopathology. There were ten (9.2%) discord-
ances between histopathology and real-time PCR for 
CK19. Five of them were positive only in the molecular 
examination, and five only in histopathology. In the 
subgroup with positive PCR for CK19, only one node 
was positive in OSNA. Perhaps these positive results 
of real-time PCR are caused by pseudogenes. At least 
two pseudo-genes for CK19, namely CK19a and CK19b, 
which have significant sequence homology with mRNA 
CK19 have been identified [48]. In the subgroup with 
positive histopathology, three nodes had positive 
OSNA result. Curiously, three lymph nodes from the 
same patient were histopathology (+), CK19 real-time 
PCR (–) but also TG real-time PCR (+). This result, and 
other differences between PCR examinations, reflect the 
heterogeneity of markers’ expression in lymph node 
metastases of PTC. If we treat histopathology as a refer-
ential examination, then the results of OSNA and both 
PCR examinations are similar. No statistically significant 
differences in the diagnostic accuracy of either method 
with regard to the histopathological examination were 
noted. There were seven differences between OSNA 
and histopathology, 11 between TG real-time PCR and 
histopathology, and ten between histopathology and 
CK19 real-time PCR. Both OSNA and real-time can be 
performed in 35 minutes or less, and thus could be per-
formed intraoperatively to detect metastases to lymph 
nodes. Real-time PCR can be very sensitive in finding 
cancer cells against a background of normal cells. It is 
able to detect histological occult micrometastases in 
many cancer types [14, 50–52]. 
Despite its advantages, real-time PCR also has its limita-
tions. It requires mRNA extracting from lymph nodes and 
its purification, next reverse transcription and PCR. These 
procedures are prone to RNA contamination and degrada-
tion, resulting in possible false positive and false negative 
outcomes. Additionally, the presence of pseudogenes 
may lead to false positive results. On the contrary, OSNA 
is highly automated. It does not require sterile working 
conditions for denaturation and hybridisation of nucleic 
acid chains. Nevertheless, lymph node harvesting in fresh 
tissue is much harder compared to formalin fixed material 
and requires special training. The OSNA assay amplifica-
tion directly starts from the lysate. Presumably OSNA 
will become cheaper. According to a Spanish cost-benefit 
analysis, the OSNA technique used in breast cancer reduces 
the number of admission days and the duration of surgery, 
and achieves a saving of about 440 euros per patient [53]. 
Conclusions
In this study, we found that OSNA is a reliable and easy 
technique for the intraoperative evaluation of lymph 
nodes in PTC. OSNA was shown to have equivalent 
accuracy to histopathology and real-time PCR. We an-
ticipate that the OSNA method will be a new alternative 
to lymph nodes evaluation in PTC, allowing for their 
whole examination with a high degree of sensitivity 
and specificity. Based on our real-time PCR outcomes, 
we suppose there is a need to assess markers other than 
CK19 for OSNA. 
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